The characteristic features of a brain with Alzheimer disease (AD) include the presence of neuritic plaques composed of amyloid 3-protein (A,B) and reductions in the levels of cholinergic markers. Neurotoxic responses to A,B have been reported in vivo and in vitro, suggesting that the cholinergic deficit in AD brain may be secondary to the degeneration of cholinergic neurons caused by Aj8. However, it remains to be determined if A,B contributes to the cholinergic deficit in AD brain by nontoxic effects. We examined the effects of synthetic A,B peptides on the cholinergic properties of a mouse cell line, SN56, derived from basal forebrain cholinergic neurons. Aj8 1-42 and Aj3 1-28 reduced the acetylcholine (AcCho) content of the cells in a concentrationdependent fashion, whereas Af3 1-16 was inactive. Maximal reductions of 43% and 33% were observed after a 48-h treatment with 100 nM of A18 1-42 and 50 pM of A18 1-28, respectively. Neither A,B 1-28 nor A,B 1-42 at a concentration of 100 nM and a treatment period of 2 weeks was toxic to the cells. Treatment of the cells with A,B 25-28 (48 h; 100 nM) significantly decreased AcCho levels, suggesting that the sequence GSNK (aa 25-28) is responsible for the AcChoreducing effect of Af3. The reductions in AcCho levels caused by A,B 1-42 and Af3 1-28 were accompanied by proportional decreases in choline acetyltransferase activity. In contrast, acetylcholinesterase activity was unaltered, indicating that A18 specifically reduces the synthesis of AcCho in SN56 cells. The reductions in AcCho content caused by AfJ 1-42 could be prevented by a cotreatment with all-trans-retinoic acid (10 nM), a compound previously shown to increase choline acetyltransferase mRNA expression in SN56 cells. These results demonstrate a nontoxic, suppressive effect of A,B on AcCho synthesis, an action that may contribute to the cholinergic deficit in AD brain.An invariant pathological feature of a brain with Alzheimer disease (AD) is the formation of the neuritic plaque, a compacted extracellular deposit of amyloid filaments surrounded by dystrophic neurites (1). This amyloid is composed of the --4-kDa amyloid 13-protein (A13), which is proteolytically derived from a 110-130 kDa transmembrane glycoprotein known as the ,B-amyloid precursor protein (,BAPP) (1). Heterogeneous processing of 1APP results in the formation of A,B peptides ranging from 39 to 43 amino acids in length (1). Several missense mutations in the j3APP gene have been linked to familial AD (2-4), and some of these have been shown to result either in excess generation of AP3 (5-7) or in a shift to the production of longer, more amyloidogenic forms (8).Overexpression of the PAPP gene, which is located on the long arm of chromosome 21, occurs in Down syndrome (trisomy 21) patients, essentially all of whom exhibit AD brain pathology by the age of 40 (9). Furthermore, transgenic mice overexpressing a mutated human ,BAPP gene display many of the pathological features of AD brain, including the neuritic plaque (10). These observati...